Seres Therapeutics (MCRB) Net Income (2014 - 2026)
Seres Therapeutics (MCRB) posted Net Income of -$25.6 million for Q1 2026, down 118.28% sequentially from $139.8 million in Q3 2024.
Seres Therapeutics (MCRB) Net Income (2014 - 2026) Analysis & Trends
Seres Therapeutics has reported Net Income for 12 years, with the latest figure at -$25.6 million in Q1 2026.
- Quarterly Net Income changed N/A year-over-year to -$25.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$25.6 million (down 119.2% YoY) and the FY2024 annual result came in at $125.9 million, up 64.79% from the prior year.
- Net Income declined to -$25.6 million in Q1 2026 per MCRB's latest filing, from $139.8 million in the prior quarter.
- Over five years, Net Income peaked at $139.8 million in Q3 2024 and troughed at -$16.5 billion in Q3 2022.
- A 4-year average of -$1.5 billion and a median of -$16.4 million in 2024 frame the typical range for Net Income.
- The sharpest annual moves came in 2022 and 2024: Net Income plunged 379.31% in 2022, then jumped 2144.32% in 2024.
- Over 4 years, Net Income stood at -$60.3 million in 2022, then soared by 89.18% to -$6.5 million in 2023, then jumped by 2240.73% to $139.8 million in 2024, then tumbled by 118.28% to -$25.6 million in 2026.
- According to Business Quant data, Net Income over the past three periods registered -$25.6 million, $139.8 million, and -$6.7 million for Q1 2026, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Seres Therapeutics | 43.87 Mn | 43.87 Mn | - | -21.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -98.45 Mn |
| Mar 31, 2026 | -25.56 Mn |
| Sep 30, 2024 | 139.81 Mn |
| Jun 30, 2024 | -6.67 Mn |
| Mar 31, 2024 | -7.23 Mn |
| Dec 31, 2023 | -6.53 Mn |
| Sep 30, 2023 | -6.84 Mn |
| Jun 30, 2023 | 44.42 Mn |
| Mar 31, 2023 | -73.97 Mn |
| Dec 31, 2022 | -60.34 Mn |
| Sep 30, 2022 | -16.47 Bn |
| Jun 30, 2022 | -917.06 Mn |
| Mar 31, 2022 | -57.48 Mn |
| Dec 31, 2021 | -49.69 Mn |
| Sep 30, 2021 | -19.81 Bn |
| Jun 30, 2021 | -191.33 Mn |
| Mar 31, 2021 | -36.91 Mn |
| Dec 31, 2020 | -22.42 Mn |
| Sep 30, 2020 | -226.03 Mn |
| Jun 30, 2020 | -30.68 Mn |